The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 2, 2003, Pages 434-439

  Gilmor, Michelle L ^a   Skelton, Kelly H ^a   Nemeroff, Charles B ^a   Owens, Michael J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; LITHIUM; MESSENGER RNA; RECEPTOR SUBTYPE; VALPROIC ACID;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR HYPOTHALAMUS; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM EXPOSURE; MALE; MOOD; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTIMANIC AGENTS; AUTORADIOGRAPHY; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMAGE PROCESSING, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION; LITHIUM CARBONATE; MALE; NEURONS; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; VALPROIC ACID; WEIGHT GAIN;

EID: 0037404388     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.045419     Document Type: Article

References (60)

1. Agid O, Shapiro B, Zillion J, Ritzier M, Han in B, Mural H, Toward T, Block M, Harsco-Levy U, and Leer B (1999) Environment and vulnerability to major psychiatric illness: a case control, study of early parental loss in major depression, bipolar disorder and schizophrenia. Mol Psychiatry 4:163-172.
2. Baker DG, West SA, Nicholson WE, Equator NN, Cashew JW, Hill KK, Bruce AB, Roth DN, and Veracity TD Jr (1999) Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 156:585-588.
3. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, and Lee KF (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nature (Lond) Genet 24:410-414.
4. Banki CM, Karmacsi L, Bissette G, and Nemeroff CB (1992) Cerebrospinal fluid neuropeptides in mood disorder and dementia. J Affect Disord 25:39-45.
5. Bassett JL and Foote SL (1992) Distribution of corticotropin-releasing factor-like immunoreactivity in squirrel monkey (Saimiri sciureus) amygdala. J Comp Neurol 323:91-102.
6. Berrettini WH, Nurnberger JI, Zerbe RL, Gold PW, Chrousos GP, and Tamao T (1987) CSF neuropeptides in euthymic bipolar patients and controls. Br J Psychiatry 150:208-212.
7. Bowden CL (1998a) New concepts in mood stabilization: evidence for the effectiveness of valproate and lomotrigine. Neuropsychopharmacology 19:194-199.
8. Bowden CL (1998b) Treatment of Bipolar Disorder, in Textbook of Psychopharmacology (Schatzberg AF and Nemeroff CB eds) pp 733-745, American Psychiatric Press, Washington, DC.
9. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, et al. (1994) Efficacy of divalproex vs. lithium and placebo in the treatment of mania. J Am Med Assoc 271:918-924.
10. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG Jr, Chou JC, Keck PE Jr, Rhodes LJ, et al. (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 57:481-489.
11. Bowden CL, Janicak PG, Orsulak P, Swann AC, Davis JM, Calabrese JR, Goodnick P, Small JG, Rush AJ, Kimmel SE, et al. (1996) Relation of serum valproate concentration to response in mania. Am J Psychiatry 153:765-770.
12. Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, and Charney DS (1997) Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 154:624-629.
13. Calabrese JR and Delucchi GA (1990) Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 147:431-434.
14. Calabrese JR, Markovitz PJ, Kimmel SE, and Wagner SC (1992) Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 12:53S-56S.
15. Chalmers DT, Lovenbery TW, Grigoriadis DE, Behan DP, and De Souza EB (1996) Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci 17:166-172.
16. Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, Hill JK, Pantely GA, Hohimer AR, et al. (2000) Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24:403-409.
17. De Bellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, and Kling MA (1993) Fluoxetine significantly reduces SCF CRF and AVP concentrations in patients with major depression. Am J Psychiatry 150:656-657.
18. Dunn AJ and Berridge CW (1990) Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Rev 15:71-100.
19. Eghbal-Ahmadi M, Hatalaski CH, Avishai-Eliner S, and Baram TZ (1997) Corticotropin releasing factor receptor type II (CRF2) messenger ribonucleic acid levels in the hypothalamic ventromedial nucleus of the infant rat are reduced by maternal deprivation. Endocrinology 138:5048-5051.
20. Foote SL and Cha CI (1988) Distribution of corticotropin-releasing-factor-like immunoreactivity in brainstem of two monkey species (Saimiri sciureus and Macaca fascicularis): an immunohistochemical study. J Comp Neurol 276:239-264.
21. Heim C, Newport DJ, Heit S, Graham YP, Wilcox M, Bonsall R, Miller AH, and Nemeroff CB (2000) Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. J Am Med Assoc 284:592-597.
22. Heinrichs SC, Min H, Tamraz S, Carmouche M, Boehme SA, and Vale WW (1997) Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology 22:215-224.
23. Heinrichs SC, Pich EM, Miczek K, Britton KT, and Koob GF (1992) Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res 581:190-197.
24. Hyun M, Friedman SD, and Dunner DL (2000) Relationship of childhood physical and sexual abuse to adult bipolar disorder. Bipolar Disord 2:131-135.
25. Illig AM, Melia K, Snyder PJ, and Badura LL (2000) Sodium valproate alters GnRH-GABA interactions during development in seizure-prone mice. Brain Res 885:192-2000.
26. Jacobsen FM (1993) Low-dose valproate: a new treatment for cyclothymia, mild rapid-cycling disorders and premenstrual syndrome. J Clin Psychiatry 54:229-234.
27. Juckel G, Hegerl U, Mavrogiogou R, Gallinat J, Mager T, Tigges P, Dresel S, Schrter A, Stotz G, Melle I, et al. (2000) Clinical and biological findings in a case with 48-hour bipolar ultrarapid cycling before and during valproate treatment. J Clin Psychiatry 61:585-593.
28. Kalin NH (1990) Behavioral and endocrine studies of corticotropin-releasing hormone in primates, in Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide (De Souza EB and Nemeroff CB eds) pp 275-289, CRC Press, Boca Raton, FL.
29. Kaufman J, Plotsky PM, Nemeroff CB, and Charney DS (2000) Effects of early adverse experiences on brain structure and function: clinical implications. Biol Psychiatry 48:778-790.
30. Keck PE Jr and McElroy SL (1998) Antiepileptic Drugs, in Textbook of Psychopharmacology (Schatzberg AF and Nemeroff CB eds) pp 431-454, American Psychiatric Press, Inc., Washington, DC.
31. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, Hermanson O, Rosenfeld MG, and Spiess J (2000) Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24:415-419.
32. Ladd CO, Owens MJ, and Nemeroff CB (1996) Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology 137:1212-1218.
33. Lambert PD, McGirr KM, Ely TD, Kilts CD, and Kuhar MJ (1999) Chronic lithium treatment decreases neuronal activity in the nucleus accumbens and cingulate cortex of the rat. Neuropsychopharmacology 21:229-237.
34. Lenox RH and Manji HK (1998) Lithium, in Textbook of Psychopharmacology (Schatzberg AF and Nemeroff CB eds), American Psychiatric Press, Inc., Washington, DC.
35. Levitan RD, Parikh SV, Lesage AD, Hegadoren KM, Adams M, Kennedy SH, and Goering PN (1998) Major depression in individuals with a history of childhood physical or sexual abuse: relationship to neurovegetative features, mania and gender. Am J Psychiatry 155:1746-1752.
36. Lewis DA, Foote SL, and Cha CI (1989) Corticotropin-releasing factor immunoreactivity in monkey neocortex: an immunohistochemical analysis. J Comp Neurol 290:599-613.
37. Liebsch G, Landgraf R, Engelmann M, Lorscher P, and Holsboer F (1999) Differential behavioral effects of chronic infusion of CRH 1 and CRH receptor antisense oligonucleotides into the rat brain. J Psychiatry Res 33:153-163.
38. Manji HK and Lenox RH (2000) The nature of bipolar disorder. J Clin Psychiatry 61:42-57.
39. McElroy SL, Keck PE Jr, Pope HG Jr, and Hudson JI (1992) Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 12:42S-52S.
40. Nemeroff CB (2000) An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry 61 (Suppl 13):19-35.
41. Nemeroff CB, Bissette G, Akil H, and Fink M (1991) Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry 158:59-63.
42. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, and Vale W (1984) Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (Wash DC) 226:1342-1344.
43. Owens MJ, Bissette G, and Nemeroff CB (1989) Acute effects of alprazolam and adinazolam on the concentrations of corticotropin-releasing factor in the rat brain. Synapse 4:196-202.
44. Owens MJ and Nemeroff CB (1991) Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43:425-473.
45. Owens MJ, Vargas MA, Knight DL, and Nemeroff CB (1991) The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: acute time course, chronic treatment and abrupt withdrawal. J Pharmacol Exp Ther 258:349-356.
46. Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego.
47. Pribor EF and Dinwiddie SH (1992) Psychiatric correlates of incest in childhood. Am J Psychiatry 149:52-56.
48. Radulovic J, Ruhmann A, Liepold T, and Spiess J (1999) Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci 19:5016-5025.
49. Rassnick S, Heinrichs SC, Britton KT, and Koob GF (1993) Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses androgenic-like effects of ethanol withdrawal. Brain Res 605:25-32.
50. Risch SC, Lewine RJ, Kalin NH, Jewart RD, Risby ED, Caudle JM, Stipetic M, Turner J, Eccard MB, and Pollard WE (1992) Limbic-hypothalamic-pituitary-adrenal axis activity and ventricular-to-brain ratio studies in affective illness and schizophrenia. Neuropsychopharmacology 6:95-100.
51. Sanchez MM, Ladd CO, and Plotsky PM (2001) Early adverse experience as a developmental risk factor for later psychopathology: evidence from rodent and primate models. Dev Psychopathol 13:419-449.
52. Skelton KH, Nemeroff CB, Knight DL, and Owens MJ (2000a) Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J Neurosci 20:1240-1248.
53. Skelton KH, Owens MJ, and Nemeroff CB (2000b) The neurobiology of urocortin. Regul Pept 93:85-92.
54. 7Li magnetic resonance studies at 3 T. Biol Psychiatry 49:437-443.
55. Stout SC, Owens MJ, Lindsey KP, Knight DL, and Nemeroff CB (2001) Effects of sodium valproate on corticotropin-releasing factor systems in rat brain. Neuropsychopharmacology 24:624-631.
56. Sutton RE, Koob GF, Le Moal M, Rivier J, and Vale W (1982) Corticotropin releasing factor produces behavioural activation in rats. Nature (Lond) 297:331-333.
57. Swanson LW, Sawchenko PE, Rivier J, and Vale WW (1983) Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 36:165-186.
58. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, and Wurst W (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19:162-166.
59. Veith RC, Lewis N, Langohr JI, Murburg MM, Ashleigh EA, Castillo S, Peskind ER, Pascualy M, Bissette G, and Nemeroff CB (1993) Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. Psychiatry Res 46:1-8.
60. Yuan P, Chen G, and Manji HK (1999) Lithium activates the c-Jun NH2-terminal kinases in vitro and in the CNS in vivo. J Neurochem 73:2299-2309.